Rowena Meyer
Adult Health · Duarte, CANPI 1609220037
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Merck at 48.6% of the total. 2025 is the largest year on record at $5,400, 6.6 times the $821 reported in 2021. Among adult health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $59.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6K
- AstraZeneca$3K
- Gilead$617
- Pfizer$521
- Daiichi Sankyo Inc.$371
- Novartis$297
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$4,54535%
- Travel & lodging$1,29810%
- Food & beverage$6,57251%
- Education$4143%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 36 | $6,229 |
| AstraZeneca(2 entities) | 56 | $2,725 |
| Gilead | 14 | $617 |
| Pfizer | 4 | $521 |
| Daiichi Sankyo Inc. | 11 | $371 |
| Novartis | 12 | $297 |
| Lilly USA, LLC | 5 | $183 |
| Stemline Therapeutics Inc. | 9 | $161 |
| GSK | 8 | $160 |
| Seagen Inc. | 4 | $155 |
| Tempus AI, Inc | 6 | $151 |
| Incyte Corporation | 6 | $143 |
| Genentech USA, Inc. | 5 | $143 |
| Astellas Pharma US Inc | 4 | $139 |
| Amgen | 8 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Sanofi | 3 | $67 |
| EMD Serono, Inc. | 2 | $54 |
| Caris MPI, Inc. | 1 | $50 |
| AbbVie | 2 | $45 |
| Bristol Myers Squibb | 2 | $43 |
| Tersera Therapeutics LLC | 1 | $39 |
| Coherus Oncology, Inc. | 1 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $33 |
| Karyopharm Therapeutics Inc. | 1 | $32 |
| Corcept Therapeutics | 1 | $31 |
| Sobi, Inc | 1 | $29 |
| Puma Biotechnology, Inc. | 1 | $27 |
| Pharmaessentia USA Corporation | 1 | $26 |
| Bayer | 1 | $24 |
| Johnson & Johnson | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,829 in reported general payments places this provider in the 95th percentile of 785 adult health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 129 | $1,931,610 |
| KisqaliRibociclib Succinate | 72 | $1,027,948 |
| VerzenioAbemaciclib | 53 | $806,139 |
| TruqapCapivasertib | 31 | $684,668 |
| OrserduElacestrant Hcl | 27 | $601,875 |
| LynparzaOlaparib | 13 | $216,713 |
| Everolimus | 24 | $60,964 |
| EliquisApixaban | 35 | $22,421 |
| XareltoRivaroxaban | 14 | $13,667 |
| FemaraLetrozole | 13 | $9,237 |
| Exemestane | 52 | $8,085 |
| Letrozole | 195 | $5,104 |
| Anastrozole | 160 | $2,971 |
| Potassium Chloride | 28 | $2,158 |
| Tamoxifen Citrate | 49 | $1,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $521 | $1,954,032164 claims |
| NovartisKisqali, Femara | $297 | $1,037,18585 claims |
| AstraZenecaTruqap, Lynparza | $2,725 | $901,38044 claims |
| Lilly USA, LLCVerzenio | $183 | $806,13953 claims |
| Stemline Therapeutics Inc.Orserdu | $161 | $601,87527 claims |
| Johnson & JohnsonXarelto | $19 | $13,66714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 785 adult health providers in California.
Other adult health in Duarte
- Melissa ScaliaDuarte$6K
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.